SILO
Silo Pharma, Inc.
Price Chart
Latest Quote
$6.12
+0.31 (+5.34%)
Current Price
| Previous Close | $5.81 |
| Open | $5.81 |
| Day High | $6.50 |
| Day Low | $5.68 |
| Volume | 98,679 |
Stock Information
| Shares Outstanding | 1.08M |
| Cash Equivalents | $6.03M |
| Revenue | $72K |
| Net Income | $-4.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.64M |
| EPS (TTM) | $-5.85 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $746K |
| Sales | $72K |
| Income | $-4.84M |
| Book/sh | $5.24 |
| Cash/sh | $5.56 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 8.56 |
| Current Ratio | 9.65 |
Returns & Margins
| ROA | -46.27% |
| ROE | -99.94% |
| Gross Margin | 11.90% |
| Operating Margin | -8846.44% |
Ownership
| Insider Ownership | 6.00% |
| Institutional Ownership | 6.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.74 |
| P/S | 92.05 |
| P/B | 1.17 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 43.16 |
| ATR | nan |
| Shares Float | 1.06M |
| Short Float | 2.06% |
| Short Ratio | 1.08 |
| Volatility | 0.75 |
| Rel Volume | 2.73 |
Performance History
| Week | -4.97% |
| Month | +9.38% |
| Quarter | +25.15% |
| 6 Months | +2.00% |
| YTD | +21.43% |
| Year | -32.45% |
| 3 Years | -81.87% |
| 5 Years | -97.14% |
| 10 Years | -97.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.12 | 99,000 |
| 2026-06-17 | $5.81 | 51,800 |
| 2026-06-16 | $6.25 | 15,900 |
| 2026-06-15 | $6.33 | 22,800 |
| 2026-06-12 | $6.63 | 19,700 |
| 2026-06-11 | $6.44 | 12,700 |
| 2026-06-10 | $6.40 | 21,800 |
| 2026-06-09 | $6.46 | 23,500 |
| 2026-06-08 | $6.26 | 29,500 |
| 2026-06-05 | $5.90 | 25,400 |
| 2026-06-04 | $6.11 | 52,800 |
| 2026-06-03 | $6.13 | 128,200 |
| 2026-06-02 | $5.25 | 31,500 |
| 2026-06-01 | $4.99 | 89,020 |
| 2026-05-29 | $6.42 | 13,920 |
| 2026-05-28 | $6.36 | 23,553 |
| 2026-05-27 | $6.26 | 8,513 |
| 2026-05-26 | $6.16 | 23,960 |
| 2026-05-22 | $5.86 | 14,767 |
| 2026-05-21 | $5.64 | 14,747 |
| 2026-05-20 | $5.59 | 10,333 |
| 2026-05-19 | $5.59 | 16,973 |
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
đ° Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-05-04T15:11:24ZEXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security
Benzinga âĸ 2025-09-23T14:16:16Z
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Benzinga âĸ 2025-09-02T11:46:10Z
Silo Pharma Second Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024)
Simply Wall St. âĸ 2025-08-15T12:44:25Z
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
TipRanks âĸ 2025-06-27T15:50:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $44,295 | $5,838 | $5,838 | $5,838 |
| Cost Of Revenue | $44,295 | $5,838 | $5,838 | $5,838 |
| Total Revenue | $72,102 | $72,102 | $72,102 | $72,102 |
| Operating Revenue | $72,102 | $72,102 | $72,102 | $72,102 |
| Expenses | ||||
| Interest Expense | $37,302 | $5,084 | $4,869 | $2,199 |
| Total Expenses | $4,352,764 | $4,777,796 | $3,927,694 | $3,719,758 |
| Other Income Expense | $-103,646 | $-15,267 | $-169,152 | $-330,170 |
| Net Non Operating Interest Income Expense | $156,610 | $328,081 | $393,661 | $70,438 |
| Interest Expense Non Operating | $37,302 | $5,084 | $4,869 | $2,199 |
| Operating Expense | $4,308,469 | $4,771,958 | $3,921,856 | $3,713,920 |
| General And Administrative Expense | $2,147,640 | $2,403,802 | $3,076,764 | $2,427,486 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,227,698 | $-4,392,880 | $-3,631,083 | $-3,907,388 |
| Net Interest Income | $156,610 | $328,081 | $393,661 | $70,438 |
| Interest Income | $193,912 | $333,165 | $398,530 | $72,637 |
| Normalized Income | $-4,124,052 | $-4,377,613 | $-3,461,931 | $-3,577,218 |
| Net Income From Continuing And Discontinued Operation | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Total Operating Income As Reported | $-4,280,662 | $-4,705,694 | $-3,855,592 | $-3,627,656 |
| Net Income Common Stockholders | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Net Income | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Net Income Including Noncontrolling Interests | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Net Income Continuous Operations | $-4,227,698 | $-4,392,880 | $-3,631,083 | $-3,907,388 |
| Pretax Income | $-4,227,698 | $-4,392,880 | $-3,631,083 | $-3,907,388 |
| Special Income Charges | $-39,916 | $0 | $-166,034 | $20,000 |
| Interest Income Non Operating | $193,912 | $333,165 | $398,530 | $72,637 |
| Operating Income | $-4,280,662 | $-4,705,694 | $-3,855,592 | $-3,647,656 |
| Gross Profit | $27,807 | $66,264 | $66,264 | $66,264 |
| Net Income Discontinuous Operations | - | $0 | $-69,600 | $-1,163 |
| Per Share | ||||
| Diluted EPS | $-7.50 | $-17.85 | $-18.00 | $-25.65 |
| Basic EPS | $-7.50 | $-17.85 | $-18.00 | $-25.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,075,310 | $-4,366,344 | $-3,457,062 | $-3,575,019 |
| Total Unusual Items | $-103,646 | $-15,267 | $-169,152 | $-330,170 |
| Total Unusual Items Excluding Goodwill | $-103,646 | $-15,267 | $-169,152 | $-330,170 |
| Reconciled Depreciation | $11,440 | $6,185 | $0 | - |
| EBITDA (Bullshit earnings) | $-4,178,956 | $-4,381,611 | $-3,626,214 | $-3,905,189 |
| EBIT | $-4,190,396 | $-4,387,796 | $-3,626,214 | $-3,905,189 |
| Diluted Average Shares | $558,818 | $245,359 | $205,324 | $152,282 |
| Basic Average Shares | $558,818 | $245,359 | $205,324 | $152,282 |
| Diluted NI Availto Com Stockholders | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $39,916 | $0 | - | - |
| Gain On Sale Of Security | $-63,730 | $-15,267 | $-3,118 | $-350,170 |
| Research And Development | $2,160,829 | $2,368,156 | $845,092 | $1,286,434 |
| Selling General And Administration | $2,147,640 | $2,403,802 | $3,076,764 | $2,427,486 |
| Other Gand A | $1,317,318 | $1,497,029 | $2,205,139 | $1,723,946 |
| Salaries And Wages | $830,322 | $906,773 | $871,625 | $577,651 |
| Other Special Charges | - | - | $166,034 | - |
| Write Off | - | - | $0 | $-20,000 |
| Insurance And Claims | - | - | $89,007 | $125,889 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,088,066 | $4,793,050 | $6,176,871 | $10,340,777 |
| Total Assets | $7,605,100 | $7,411,840 | $7,746,141 | $11,642,877 |
| Total Non Current Assets | $217,375 | $300,360 | $64,983 | $70,821 |
| Goodwill And Other Intangible Assets | $217,375 | $241,215 | $0 | - |
| Other Intangible Assets | $217,375 | $241,215 | - | - |
| Current Assets | $7,387,725 | $7,111,480 | $7,681,158 | $11,572,056 |
| Other Current Assets | $208,559 | $30,957 | $15,970 | $135,894 |
| Cash Cash Equivalents And Short Term Investments | $7,179,166 | $7,080,523 | $7,665,188 | $11,370,152 |
| Cash And Cash Equivalents | $4,748,700 | $3,905,799 | $3,524,308 | $11,367,034 |
| Other Non Current Assets | - | $59,145 | $64,983 | $70,821 |
| Receivables | - | - | $0 | $66,010 |
| Notes Receivable | - | - | $0 | $66,010 |
| Non Current Note Receivables | - | - | - | $0 |
| Prepaid Assets | - | - | - | $135,894 |
| Accrued Interest Receivable | - | - | - | $6,010 |
| Non Current Prepaid Assets | - | - | - | - |
| Assets Held For Sale Current | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,299,659 | $2,377,575 | $1,569,270 | $1,302,100 |
| Total Non Current Liabilities Net Minority Interest | $649,476 | $721,578 | $793,680 | $865,782 |
| Non Current Deferred Liabilities | $649,476 | $721,578 | $793,680 | $865,782 |
| Current Liabilities | $650,183 | $1,655,997 | $775,590 | $436,318 |
| Current Deferred Liabilities | $72,102 | $72,102 | $72,102 | $72,102 |
| Payables And Accrued Expenses | $578,081 | $1,583,895 | $703,488 | $364,216 |
| Payables | - | - | - | $364,216 |
| Accounts Payable | - | - | - | $364,216 |
| Equity | ||||
| Common Stock Equity | $6,305,441 | $5,034,265 | $6,176,871 | $10,340,777 |
| Total Equity Gross Minority Interest | $6,305,441 | $5,034,265 | $6,176,871 | $10,340,777 |
| Stockholders Equity | $6,305,441 | $5,034,265 | $6,176,871 | $10,340,777 |
| Gains Losses Not Affecting Retained Earnings | $5,828 | $2,419 | $-6,227 | $0 |
| Other Equity Adjustments | $5,828 | $2,419 | $-6,227 | - |
| Retained Earnings | $-19,492,389 | $-15,264,691 | $-10,871,811 | $-7,171,128 |
| Other | ||||
| Ordinary Shares Number | $13,318,273 | $4,484,456 | $2,906,241 | $3,158,797 |
| Share Issued | $13,318,273 | $4,484,456 | $3,159,096 | $3,158,797 |
| Tangible Book Value | $6,088,066 | $4,793,050 | $6,176,871 | $10,340,777 |
| Invested Capital | $6,305,441 | $5,034,265 | $6,176,871 | $10,340,777 |
| Working Capital | $6,737,542 | $5,455,483 | $6,905,568 | $11,135,738 |
| Total Capitalization | $6,305,441 | $5,034,265 | $6,176,871 | $10,340,777 |
| Treasury Stock | $0 | $0 | $471,121 | $0 |
| Additional Paid In Capital | $25,790,670 | $20,296,088 | $17,525,714 | $17,511,589 |
| Capital Stock | $1,332 | $449 | $316 | $316 |
| Common Stock | $1,332 | $449 | $316 | $316 |
| Non Current Deferred Revenue | $649,476 | $721,578 | $793,680 | $865,782 |
| Current Deferred Revenue | $72,102 | $72,102 | $72,102 | $72,102 |
| Other Short Term Investments | $2,430,466 | $3,174,724 | $4,140,880 | $3,118 |
| Treasury Shares Number | - | $0 | $252,855 | - |
| Preferred Stock | - | - | $0 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,236,259 | $-3,833,914 | $-3,224,498 | $-3,497,622 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,661,339 | $-3,833,914 | $-3,224,498 | $-3,497,622 |
| Cash Flow From Continuing Operating Activities | $-4,661,339 | $-3,833,914 | $-3,224,498 | $-3,497,622 |
| Operating Gains Losses | $-3,911 | $1,025 | - | $104,700 |
| Cash From Discontinued Operating Activities | - | - | - | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-574,920 | - | - | - |
| Investing Cash Flow | $644,021 | $973,777 | $-4,147,107 | $86,707 |
| Cash Flow From Continuing Investing Activities | $644,021 | $973,777 | $-4,147,107 | $86,707 |
| Net Other Investing Changes | - | - | - | $20,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-173,113 | $-471,121 | $0 |
| Issuance Of Capital Stock | $3,725,236 | $3,414,738 | $0 | $4,940,948 |
| Financing Cash Flow | $4,860,219 | $3,241,628 | $-471,121 | $4,940,948 |
| Cash Flow From Continuing Financing Activities | $4,860,219 | $3,241,628 | $-471,121 | $4,940,948 |
| Net Common Stock Issuance | $3,725,236 | $3,241,625 | $-471,121 | $4,940,948 |
| Common Stock Issuance | $3,725,236 | $3,414,738 | $0 | $4,940,948 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $37,302 | $5,084 | $4,869 | $2,199 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $25,159 |
| End Cash Position | $4,748,700 | $3,905,799 | $3,524,308 | $11,367,034 |
| Beginning Cash Position | $3,905,799 | $3,524,308 | $11,367,034 | $9,837,001 |
| Changes In Cash | $842,901 | $381,491 | $-7,842,726 | $1,530,033 |
| Proceeds From Stock Option Exercised | $1,134,983 | $3 | $0 | - |
| Common Stock Payments | $0 | $-173,113 | $-471,121 | $0 |
| Net Investment Purchase And Sale | $1,218,941 | $973,777 | $-4,147,107 | $66,707 |
| Sale Of Investment | $1,315,653 | $1,149,320 | $0 | $66,707 |
| Purchase Of Investment | $-96,712 | $-175,543 | $-4,147,107 | - |
| Net Intangibles Purchase And Sale | $-574,920 | $0 | - | - |
| Purchase Of Intangibles | $-574,920 | $0 | - | - |
| Change In Working Capital | $-1,183,973 | $551,756 | $299,275 | $-75,288 |
| Change In Other Working Capital | $-72,102 | $-72,102 | $-72,102 | $-72,102 |
| Change In Payables And Accrued Expense | $-993,414 | $633,007 | $339,272 | $-53,721 |
| Change In Prepaid Assets | $-118,457 | $-9,149 | $35,695 | $55,335 |
| Other Non Cash Items | $518,018 | - | $90,067 | $-85,733 |
| Stock Based Compensation | $117,021 | $0 | $14,125 | $156,047 |
| Unrealized Gain Loss On Investment Securities | $67,848 | $0 | $3,118 | $331,203 |
| Asset Impairment Charge | $39,916 | $0 | $0 | $-20,000 |
| Depreciation Amortization Depletion | $11,440 | $6,185 | $0 | - |
| Depreciation And Amortization | $11,440 | $6,185 | $0 | - |
| Amortization Cash Flow | $11,440 | $6,185 | $0 | - |
| Amortization Of Intangibles | $11,440 | $6,185 | $0 | - |
| Gain Loss On Investment Securities | $-3,911 | $1,025 | - | $104,700 |
| Net Income From Continuing Operations | $-4,227,698 | $-4,392,880 | $-3,700,683 | $-3,908,551 |
| Change In Receivables | - | $0 | $-3,590 | $-4,800 |
| Change In Payable | - | - | $339,272 | $-53,721 |
| Change In Account Payable | - | - | $339,272 | $-53,721 |
| Provisionand Write Offof Assets | - | - | $69,600 | $0 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-17